Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSVCBD in Relapsed/Refractory AQP4-Positive NMOSD
NCT07592754Phase 1Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Chinese PLA General Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events and Serious Adverse Events at 24 months and 1 more. Planned start May 2026; status: not yet recruiting.
02
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT07592754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07592754.